Text Size

The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by Rambam Health Care Campus.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00498667
First received: July 8, 2007
Last updated: July 26, 2011
Last verified: June 2007
History of Changes
  Purpose

A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.


Condition
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma

Resource links provided by NLM:

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Biospecimen Description:

no biopsies are to be retained


Estimated Enrollment: 150
Study Start Date: December 2006
Estimated Study Completion Date: December 2011
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
PET/CT
all patients with aggressive lymphoma who had a baseline and interim pet/ct study

Detailed Description:

Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

all patients with agressive non hodgkin lymphoma who had interim pet/ct during therapy

Criteria

Inclusion Criteria:

  • aggressive non-Hodgkin lymphoma b cells
  • age 18-70
  • bilirubin less then 2
  • creatinine less then 2
  • Pet/CT performed post 2 cycles

Exclusion Criteria:

  • no PET/CT post 2 cycles performed
  • bilirubin >2
  • creatinine more then 2
  • HIV positivity
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00498667

Locations
Israel
RAMBAM health care Campus
Haifa, Israel, 31096
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Eldad J Dann, MD RAMBAM health care campus,Rappaport faculty of medicine Technion Israel Technical institute
  More Information

No publications provided

Responsible Party: Eldad J Dann, Eldad J Dann RAMBAM Health care campus
ClinicalTrials.gov Identifier: NCT00498667     History of Changes
Other Study ID Numbers: cc-NHL2615_CTIL
Study First Received: July 8, 2007
Last Updated: July 26, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:
PET/CT
Aggressive non-Hodgkin Lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
 Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 22, 2013